|
|
| Line 1: |
Line 1: |
| {| class="wikitable sortable"
| | <ref name="J Sidener">{{cite news |
| ! align="center" style="background:#f0f0f0;"|'''Title of Guidelines'''
| | | first = Jonathan |
| ! align="center" style="background:#f0f0f0;"|'''Year'''
| | | last = Sidener |
| ! align="center" style="background:#f0f0f0;"|'''Class III Recommendation'''
| | | title = Wikipedia family feud rooted in San Diego |
| ! align="center" style="background:#f0f0f0;"|'''Level of Evidence'''
| | | url = http://www.signonsandiego.com/news/tech/personaltech/20061009-9999-mz1b9wikiped.html |
| ! align="center" style="background:#f0f0f0;"|'''Effect'''
| | | publisher = [[The San Diego Union-Tribune]] |
| ! align="center" style="background:#f0f0f0;"|'''Key Word'''
| | | date = October 9, 2006 |
| |-
| | | accessdate = May 5, 2009 |
| | ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery ||2014||Routine use of pulmonary artery catheterization in patients, even those with elevated risk, is not recommended.||A||No Benefit||Cardiac evaluation for non cardiac surgery
| | }}</ref> |
| |- | |
| | ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery||2009||Routine use of a PAC perioperatively, especially in patients at low risk of developing hemodynamic disturbances, is not recommended.||A||N/A||Perioperative Beta Blockade
| |
| |-
| |
| | ACCF/AHA Guideline for the Management of Heart Failure||2013||Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use.||A||No Benefit||Heart failure
| |
| |-
| |
| | ACCF/AHA Guideline for the Management of Heart Failure ||2013||Calcium channel–blocking drugs are not recommended as routine treatment for patients with HFrEF ||A||No Benefit||Heart failure
| |
| |-
| |
| | ACCF/AHA Guideline for the Management of Heart Failure ||2013||Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. ||A||No Benefit||Heart failure
| |
| |-
| |
| | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease ||2012||Estrogen therapy is not recommended in postmenopausal women with SIHD with the intent of reducing cardiovascular risk or improving clinical outcomes.||A||No Benefit||Ischemic heart disease
| |
| |-
| |
| | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease ||2012||Treatment of elevated homocysteine with folate or vitamins B6 and B12 is not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD.||A||No Benefit||Ischemic heart disease
| |
| |-
| |
| | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease ||2012||Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD.||A||No Benefit||Ischemic heart disease
| |
| |-
| |
| | ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention ||2011||Administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced acute kidney injury.||A||No Benefit||PCI
| |
| |-
| |
| | ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention ||2011||Cutting balloon angioplasty should not be performed routinely during PCI.||A||No Benefit||PCI
| |
| |-
| |
| | ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention ||2011||Laser angioplasty should not be used routinely during PCI.||A||No Benefit||PCI
| |
| |-
| |
| | ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention ||2011||Rotational atherectomy should not be performed routinely for de novo lesions or in-stent restenosis.||A||No Benefit||PCI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes ||2014||Antioxidant vitamin supplements (eg, vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS.||A||No Benefit||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes ||2014||Folic acid, with or without vitamins B6 and B12, should not be used for secondary prevention in patients with NSTE-ACS.||A||No Benefit||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes ||2014||Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks.||A||Harm||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes ||2014||In patients with NSTE-ACS (ie, without ST-elevation, true posterior Ml, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used.||A||Harm||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes ||2014||With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS. ||A||No Benefit||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease ||2014||Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D).||A||No Benefit|| Valvular heart disease
| |
| |-
| |
| | AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science||2010||Management of Arrhythmias,Ventricular Rhythm Disturbances Prophylactic administration of lidocaine is not recommended ||A||N/A|| Cardiopulmonary Resuscitation
| |
| |-
| |
| | AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science||2010||Management of Arrhythmias,Ventricular Rhythm Disturbances Pprophylactic antiarrhythmics are not recommended for patients with suspected ACS or myocardial infarction in the prehospital or ED||A||N/A|| Cardiopulmonary Resuscitation
| |
| |-
| |
| | AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science||2010||Cardiac Arrest Associated With Pulmonary Embolism In patients with cardiac arrest and without known PE, routine fibrinolytic treatment given during CPR shows no benefit185,186 and is not recommended ||A||N/A|| Cardiopulmonary Resuscitation
| |
| |-
| |
| | AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science||2010||Other Vasopressors,Magnesium Sulfate Routine administration of magnesium sulfate in cardiac arrest is not recommended unless torsades de pointes is present.||A||N/A|| Cardiopulmonary Resuscitation
| |
| |-
| |
| | ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease ||2008||Pregnancy in patients with ASD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged.||A||N/A||Congenital heart disease
| |
| |-
| |
| | ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease ||2008||Pregnancy in patients with VSD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged. ||A||N/A||Congenital heart disease
| |
| |-
| |
| | ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery||2014||Routine use of pulmonary artery catheterization in patients, even those with elevated risk, is not recommended.||A||No Benefit||Cardiac risk evaluation for non-cardiac surgery
| |
| |-
| |
| | ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults||2013||CK should not be routinely measured in individuals receiving statin therapy.||A||No benefit||Dyslipidemia
| |
| |-
| |
| | ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults||2013||It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.||A||Harm||Dyslipidemia
| |
| |-
| |
| | ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) ||2005||Chelation (e.g., ethylenediaminetetraacetic acid) is not indicated for treatment of intermittent claudication and may have harmful adverse effects. ||A||N/A||Peripheral arterial disease
| |
| |-
| |
| | ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) ||2005||Intervention is not recommended for asymptomatic infrarenal or juxtarenal AAAs if they measure less than 5.0 cm in diameter in men or less than 4.5 cm in diameter in women.||A||N/A||Peripheral arterial disease
| |
| |-
| |
| | ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) ||2005||Oral vasodilator prostaglandins such as beraprost and iloprost are not effective medications to improve walking distance in patients with intermittent claudication.||A||N/A||Peripheral arterial disease
| |
| |-
| |
| | ACC/AHA/ESC Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death ||2006||Class IC antiarrhythmic drugs in patients with a past history of MI should not be used.||A||No Benefit||Ventricular arrhythmias
| |
| |-
| |
| | ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities||2008||Permanent pacing is not indicated for torsade de pointes VT due to reversible causes.||A||N/A||Device-based therapy
| |
| |-
| |
| | ACCF/AHA Guideline for the Management of Heart Failure||2013||Calcium channel–blocking drugs are not recommended as routine treatment for patients with HFrEF.||A||No Benefit||Heart Failure
| |
| |-
| |
| | ACCF/AHA Guideline for the Management of Heart Failure||2013||Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use||A||No Benefit||Heart Failure
| |
| |-
| |
| | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease||2012||Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD||A||No Benefit||Stable ischemic heart disease
| |
| |-
| |
| | ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities||2008||Permanent pacing is not indicated for torsade de pointes VT due to reversible causes.||A||N/A||Cardiac Rhythm Abnormalities
| |
| |-
| |
| | AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery||2015||Among patients with LV dysfunction (EF <35%), ICD therapy is not recommended for the prevention of sudden cardiac death after CABG until 3 months of postoperative goal-directed medical therapy has been provided and persistent LV dysfunction has been confirmed ||A||N/A||CABG
| |
| |-
| |
| | AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery||2015||Warfarin should not be routinely prescribed after CABG for graft patency unless patients have other indications for long-term antithrombotic therapy (such as AF, venous thromboembolism, or a mechanical prosthetic valve)||A||N/A||CABG
| |
| |-
| |
| | AHA Scientific Statement: Diagnosis and Treatment of Fetal Cardiac Disease||2014||Fetal medical therapy is of no benefit for fetuses with sinus bradycardia, irregular rhythms caused by extrasystolic beats.||A||N/A||Fetal cardiac disease
| |
| |-
| |
| | AHA Scientific Statement: Diagnosis and Treatment of Fetal Cardiac Disease||2014||Referral for fetal cardiac evaluation is not indicated for maternal medications including SSRIs (other than paroxetine).||A||N/A||Fetal cardiac disease
| |
| |-
| |
| | AHA Scientific Statement: Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension||2011||Systemic fibrinolysis should not be given routinely to patients with IFDVT.||A||N/A||Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
| |
| |-
| |
| | AHA Scientific Statement: The Postthrombotic Syndrome Evidence-Based Prevention, Diagnosis, and Treatment Strategies||2014||Recommendations for Thrombolysis and Endovascular Approaches to Acute DVT for the Prevention of PTS Systemic thrombolysis is not recommended for the treatment of DVT||A||N/A||Postthrombotic Syndrome
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes||2014||Antioxidant vitamin supplements (eg, vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS.||A||No Benefit||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes||2014||Folic acid, with or without vitamins B6 and B12, should not be used for secondary prevention in patients with NSTE-ACS.||A||No Benefit||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes||2014||Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks.||A||Harm||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes||2014||In patients with NSTE-ACS (ie, without ST-elevation, true posterior MI, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used.||A||Harm||NSTEMI
| |
| |- | |
| | AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes||2014||With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS.||A||No Benefit||NSTEMI
| |
| |-
| |
| | AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease||2014||Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D).||A||No Benefit||Valvular heart disease
| |
| |-
| |
| | AHA Scientific Statement: Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates||2012||Initiating beta-blocker therapy in beta-blocker–naïve patients the night before and/or the morning of noncardiac surgery is not recommended ||A||N/A||Kidney and Liver Transplantation Candidates
| |
| |-
| |
| | Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease ||2011||Except in extraordinary circumstances, carotid revascularization by either CEA or CAS is not recommended when atherosclerosis narrows the lumen by less than 50%.||A||No Benefit||Extracranial Carotid and Vertebral Artery Disease
| |
| |-
| |
| | AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack||2014||For patients with a cryptogenic ischemic stroke or TIA and a PFO without evidence for DVT, available data do not support a benefit for PFO closure||A||N/A||Prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack||2014||For patients with a recent (within 6 months) TIA or ischemic stroke ipsilateral to a stenosis or occlusion of the middle cerebral or carotid artery, EC/IC bypass surgery is not recommended||A||N/A||Prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack||2014||Routine supplementation with a single vitamin or combination of vitamins is not recommended||A||N/A||Prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack||2014||The combination of aspirin and clopidogrel, when initiated days to years after a minor stroke or TIA and continued for 2 to 3 years, increases the risk of hemorrhage relative to either agent alone and is not recommended for routine long-term secondary prevention after ischemic stroke or TIA||A||N/A||Prevention of stroke
| |
| |- | |
| | AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack||2014||When the degree of stenosis is <50%, CEA and CAS are not recommended||A||N/A||Prevention of stroke
| |
| |- | |
| | AHA/ASA Guidelines for the Primary Prevention of Stroke||2011||Aspirin is not useful for preventing a first stroke in persons at low risk||A||N/A||Primary prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Primary Prevention of Stroke||2011||Hormone therapy (CEE with or without MPA) should not be used for primary prevention of stroke in postmenopausal women||A||N/A||Primary prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Primary Prevention of Stroke||2011||Screening for cardiac conditions such as PFO in the absence of neurological conditions or a specific cardiac cause is not recommended||A||N/A||Primary prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Primary Prevention of Stroke||2011||SERMs, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke||A||N/A||Primary prevention of stroke
| |
| |-
| |
| | AHA/ASA Guidelines for the Primary Prevention of Stroke||2011||Treatment with antibiotics for chronic infections as a means to prevent stroke is not recommended||A||N/A||Primary prevention of stroke
| |
| |-
| |
| | ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery||2009||Routine use of a PAC perioperatively, especially in patients at low risk of developing hemodynamic disturbances, is not recommended.||A||N/A||Perioperative Beta Blockade
| |
| |-
| |
| | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease||2012||Estrogen therapy is not recommended in postmenopausal women with SIHD with the intent of reducing cardiovascular risk or improving clinical outcomes.||A||No Benefit||Stable ischemic heart disease
| |
| |-
| |
| | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease||2012||Treatment of elevated homocysteine with folate or vitamins B6 and B12 is not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD||A||No Benefit||Stable ischemic heart disease
| |
| |}
| |